S&P 500   3,795.09 (+0.11%)
DOW   30,364.79 (+0.16%)
QQQ   282.02 (-0.04%)
AAPL   146.33 (+0.16%)
MSFT   249.37 (+0.20%)
META   138.97 (-0.93%)
GOOGL   101.19 (-0.44%)
AMZN   120.96 (-0.11%)
TSLA   239.72 (-3.90%)
NVDA   131.87 (+0.15%)
NIO   15.99 (-4.42%)
BABA   84.46 (+0.42%)
AMD   68.04 (+0.21%)
T   15.95 (-0.87%)
MU   54.75 (+1.46%)
CGC   3.03 (-3.50%)
F   12.46 (+0.81%)
GE   67.87 (+0.49%)
DIS   100.44 (-0.99%)
AMC   7.43 (-5.11%)
PYPL   93.98 (+1.28%)
PFE   44.15 (-0.70%)
NFLX   236.21 (-1.88%)
S&P 500   3,795.09 (+0.11%)
DOW   30,364.79 (+0.16%)
QQQ   282.02 (-0.04%)
AAPL   146.33 (+0.16%)
MSFT   249.37 (+0.20%)
META   138.97 (-0.93%)
GOOGL   101.19 (-0.44%)
AMZN   120.96 (-0.11%)
TSLA   239.72 (-3.90%)
NVDA   131.87 (+0.15%)
NIO   15.99 (-4.42%)
BABA   84.46 (+0.42%)
AMD   68.04 (+0.21%)
T   15.95 (-0.87%)
MU   54.75 (+1.46%)
CGC   3.03 (-3.50%)
F   12.46 (+0.81%)
GE   67.87 (+0.49%)
DIS   100.44 (-0.99%)
AMC   7.43 (-5.11%)
PYPL   93.98 (+1.28%)
PFE   44.15 (-0.70%)
NFLX   236.21 (-1.88%)
S&P 500   3,795.09 (+0.11%)
DOW   30,364.79 (+0.16%)
QQQ   282.02 (-0.04%)
AAPL   146.33 (+0.16%)
MSFT   249.37 (+0.20%)
META   138.97 (-0.93%)
GOOGL   101.19 (-0.44%)
AMZN   120.96 (-0.11%)
TSLA   239.72 (-3.90%)
NVDA   131.87 (+0.15%)
NIO   15.99 (-4.42%)
BABA   84.46 (+0.42%)
AMD   68.04 (+0.21%)
T   15.95 (-0.87%)
MU   54.75 (+1.46%)
CGC   3.03 (-3.50%)
F   12.46 (+0.81%)
GE   67.87 (+0.49%)
DIS   100.44 (-0.99%)
AMC   7.43 (-5.11%)
PYPL   93.98 (+1.28%)
PFE   44.15 (-0.70%)
NFLX   236.21 (-1.88%)
S&P 500   3,795.09 (+0.11%)
DOW   30,364.79 (+0.16%)
QQQ   282.02 (-0.04%)
AAPL   146.33 (+0.16%)
MSFT   249.37 (+0.20%)
META   138.97 (-0.93%)
GOOGL   101.19 (-0.44%)
AMZN   120.96 (-0.11%)
TSLA   239.72 (-3.90%)
NVDA   131.87 (+0.15%)
NIO   15.99 (-4.42%)
BABA   84.46 (+0.42%)
AMD   68.04 (+0.21%)
T   15.95 (-0.87%)
MU   54.75 (+1.46%)
CGC   3.03 (-3.50%)
F   12.46 (+0.81%)
GE   67.87 (+0.49%)
DIS   100.44 (-0.99%)
AMC   7.43 (-5.11%)
PYPL   93.98 (+1.28%)
PFE   44.15 (-0.70%)
NFLX   236.21 (-1.88%)
NYSE:NUVB

Nuvation Bio - NUVB Stock Forecast, Price & News

$2.51
+0.06 (+2.45%)
(As of 10/5/2022 02:57 PM ET)
Add
Compare
Today's Range
$2.41
$2.51
50-Day Range
$1.99
$3.13
52-Week Range
$1.92
$10.45
Volume
39,219 shs
Average Volume
645,706 shs
Market Capitalization
$547.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Nuvation Bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
59.4% Upside
$4.00 Price Target
Short Interest
Healthy
5.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.53) to ($0.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

348th out of 1,087 stocks

Pharmaceutical Preparations Industry

156th out of 546 stocks

NUVB stock logo

About Nuvation Bio (NYSE:NUVB) Stock

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

Receive NUVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter.

NUVB Stock News Headlines

Short Volatility Alert: Nuvation Bio Inc.
See More Headlines
Receive NUVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter.

NUVB Company Calendar

Last Earnings
8/04/2022
Today
10/05/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
64
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$2.50
Forecasted Upside/Downside
+59.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-86,850,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.42 per share

Miscellaneous

Free Float
142,404,000
Market Cap
$547.78 million
Optionable
Not Optionable
Beta
0.56

Key Executives

  • Dr. David T. Hung M.D.Dr. David T. Hung M.D. (Age 64)
    Founder, Pres, CEO & Director
    Comp: $1.18M
  • Ms. Jennifer A. FoxMs. Jennifer A. Fox (Age 50)
    CFO & Sec.
    Comp: $1.01M
  • Dr. David C. Hanley Ph.D. (Age 52)
    Chief Technical Operations Officer
    Comp: $497.14k
  • Dr. Gary Hattersley Ph.D. (Age 55)
    Chief Scientific Officer
  • Ms. Stacy Markel (Age 57)
    Chief People Officer
  • Ms. Melanie Morrison
    Sr. VP of Clinical Operations & Program Management
  • Ms. Kerry A. Wentworth (Age 49)
    Chief Regulatory Officer
  • Dr. David Liu M.D.
    Ph.D., Chief Medical Officer













NUVB Stock - Frequently Asked Questions

Should I buy or sell Nuvation Bio stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nuvation Bio in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NUVB shares.
View NUVB analyst ratings
or view top-rated stocks.

What is Nuvation Bio's stock price forecast for 2022?

4 equities research analysts have issued 12-month price targets for Nuvation Bio's stock. Their NUVB share price forecasts range from $2.50 to $5.00. On average, they predict the company's share price to reach $4.00 in the next year. This suggests a possible upside of 59.4% from the stock's current price.
View analysts price targets for NUVB
or view top-rated stocks among Wall Street analysts.

How have NUVB shares performed in 2022?

Nuvation Bio's stock was trading at $9.70 at the start of the year. Since then, NUVB stock has decreased by 74.1% and is now trading at $2.51.
View the best growth stocks for 2022 here
.

When is Nuvation Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our NUVB earnings forecast
.

How were Nuvation Bio's earnings last quarter?

Nuvation Bio Inc. (NYSE:NUVB) posted its quarterly earnings results on Thursday, August, 4th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.03.

What is Nuvation Bio's stock symbol?

Nuvation Bio trades on the New York Stock Exchange (NYSE) under the ticker symbol "NUVB."

How do I buy shares of Nuvation Bio?

Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nuvation Bio's stock price today?

One share of NUVB stock can currently be purchased for approximately $2.51.

How much money does Nuvation Bio make?

Nuvation Bio (NYSE:NUVB) has a market capitalization of $547.78 million. The company earns $-86,850,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis.

How can I contact Nuvation Bio?

Nuvation Bio's mailing address is 1500 BROADWAY SUITE 1401, NEW YORK NY, 10036. The official website for the company is www.nuvationbio.com. The company can be reached via phone at 332-208-6102 or via email at ir@nuvationbio.com.

This page (NYSE:NUVB) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.